Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com

Articles

Belantamab Mafodotin/Pembrolizumab Combo Elicits Favorable ORR in Heavily Pretreated Multiple Myeloma

July 26th 2022

The addition of pembrolizumab to belantamab mafodotin resulted in a higher overall response rate in patients with relapsed/refractory multiple myeloma than what has been observed with the antibody-drug conjugate alone, according to results from the phase 1/2 DREAMM-4 trial.

Immunotherapy May Represent an Exciting Development in Angiosarcoma Treatment

July 25th 2022

Although systemic treatments are utilized for angiosarcoma, an aggressive and rare subset of a rare cancer, the efficacy achieved with these options is not as good as it needs to be. Immunotherapy may be able to address the unmet need for a systemic treatment in this disease.

ASCO, ACCC Issue Recommendations to Boost Clinical Trial Diversity

July 24th 2022

The American Society of Clinical Oncology and the Association of Community Cancer Centers have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.

Intrinsic Tumor Subtyping Is Key To Breast Cancer Treatment

July 15th 2022

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

NCCN Releases New Guidelines for Pediatric CNS Cancers

July 13th 2022

The National Comprehensive Cancer Network issued recommendations for providers treating children with brain cancers.

Cabozantinib Demonstrates Long-Term PFS Benefit in Radioiodine-Refractory Differentiated Thyroid Cancer

July 13th 2022

Cabozantinib monotherapy maintained continued to provide a superior progression-free survival benefit to that achieved with placebo in adults with locally advanced or metastatic differentiated thyroid carcinoma, irrespective of histology, according to updated data from the phase 3 COSMIC-311 trial.

FDA Grants Orphan Drug, Fast Track Designations to CV-01 in Recurrent Glioblastoma

July 13th 2022

CV-01, Alpheus Medical’s novel sonodynamic therapy delivery platform, has received orphan drug and fast track designations from the FDA for the treatment of patients with recurrent glioblastoma.

Survival is Significantly Poorer for Young Black Patients With AML Compared With White Counterparts

July 11th 2022

Despite receiving similar treatment, Black patients between the ages of 18 and 29 years with acute myeloid leukemia were twice as likely to die within 5 years compared with Whites.

Short Course of Oxaliplatin/Fluoropyrimidine Noninferior for DFS, Neuropathy in High-Risk CRC

July 11th 2022

A 3-month course of oxaliplatin produced disease-free survival noninferior to a 6-month course in patients with high-risk stage II and III colorectal cancer.

Enfortumab Vedotin Maintains Long-Term OS Benefit in Advanced Urothelial Carcinoma

July 3rd 2022

Enfortumab vedotin extended overall survival by 3.97 months compared with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

Disitamab Vedotin Shows Efficacy in HER2-Negative Metastatic Urothelial Carcinoma

June 30th 2022

Disitamab vedotin demonstrated promising efficacy with a tolerable safety profile in patients with HER2-negative metastatic urothelial carcinoma.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Orelabrutinib/Sintilimab Combo Induces Rapid Responses in Peripheral CNS Lymphoma

June 29th 2022

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

Penile Cancer Is Treatable, But the Armamentarium is Thin

June 28th 2022

Among men in the United States, incidence-based mortality is growing for penile cancer even though incidence remained consistent from 2000 to 2018.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

Japanese Regulatory Approval Sought for Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer

June 27th 2022

A supplemental New Drug Application has been submitted to Japan’s Ministry of Health, Labour, and Welfare seeking approval for use of trastuzumab deruxtecan for the treatment of adult patients with HER2-low unresectable or recurrent metastatic breast cancer following chemotherapy

NCCN Adds Trastuzumab Deruxtecan, Sacituzumab Govitecan to Guidelines for Advanced Breast Cancer

June 23rd 2022

“Compelling” data support the use of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer and the use of sacituzumab govitecan for patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

New USPSTF Guidelines Increase Lung Cancer Screening Among African Americans

June 22nd 2022

The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.

EMA Accepts Type II Application for Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

June 22nd 2022

The European Medicines Agency has validated a Type II Variation application for trastuzumab deruxtecan as monotherapy for adults with unresectable or metastatic HER2-low breast cancer.

RG6234 Is Highly Active in Relapsed/Refractory Multiple Myeloma

June 13th 2022

RG6234, a novel T-cell engaging bispecific antibody with a 2:1 configuration, induced high response rates and early evidence of durability for patients with relapsed/refractory multiple myeloma.